Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 06 2021 - 7:00AM
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Company management will participate
in a fireside chat at the BTIG Virtual Biotechnology Conference on
Tuesday, August 10, 2021, at 1:00 p.m. ET.
BTIG hosted events are intended for prospective
and existing BTIG clients only. To listen to the live event, please
contact your BTIG representative.
About Yumanity
TherapeuticsYumanity Therapeutics is a clinical-stage
biopharmaceutical company dedicated to accelerating the revolution
in the treatment of neurodegenerative diseases through its
scientific foundation and drug discovery platform. The Company’s
most advanced product candidate, YTX-7739, is currently in Phase 1
clinical development for Parkinson’s disease. Yumanity’s drug
discovery platform enables the Company to rapidly screen for
potential disease-modifying therapies by overcoming the toxicity of
misfolded proteins associated with neurogenerative diseases.
Yumanity’s pipeline consists of additional programs focused on Lewy
body dementia, multi-system atrophy, amyotrophic lateral sclerosis
(ALS or Lou Gehrig’s disease), frontotemporal lobar dementia
(FTLD), and Alzheimer’s disease. For more information, please
visit www.yumanity.com.
Investors:Burns McClellan,
Inc.Lee Rothlroth@burnsmc.com (212) 213-0006
Media:Burns McClellan,
Inc.Robert Flamm, Ph.D. / Harrison Wongrflamm@burnsmc.com /
hwong@burnsmc.com (212) 213-0006 ext. 364 / 316
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024